健友作为一体化医药集团,构建了药品研发、生产、销售完整业务体系,始终聚焦高端无菌制剂,持续为全球市场提供高品质医药产品。
我们始终专注于为患者提供更优治疗方案——从新药研发到剂型与包装形式的持续优化。
-
80+ANDA -
30+生物药 -
3+创新药
健友NKF致力于建设具有国际竞争力的全球化团队,持续打造守护生命健康的产品,并以实际行动履行对环境保护的长期承诺。
最新消息
-
公司新闻NKF's Propofol Injectable Emulsion has been approved by the US FDA and is about to enter the US market!
2025-12-05 -
公司新闻NKF's subsidiary Kindos's Dalbavancin for Injection gets FDA approval for marketing
2025-12-03 -
公司新闻NKF sincerely invites global customers to gather at CPHI Europe to explore new opportunities for cooperation together!
2025-10-21 -
公司新闻NKF attended the 25th anniversary celebration of GMS in Pakistan to deepen strategic cooperation
2025-10-17 -
公司新闻NKF's subsidiary Kindos's Etoposide Injection gets FDA approval for marketing
2025-08-04 -
公司新闻NKF makes its debut at CPHI Southeast Asia
2025-07-21 -
公司新闻King-Friend will meet you in CPHI Malaysia!
2025-07-14 -
公司新闻NKF's subsidiary Kindos's Hydralazine Hydrochloride Injection gets FDA
2025-06-09